Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 329 entries
View as:

Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05106374 Org: User:
Start: 09/04/18 End: 12/31/25 Due: 12/31/26

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00834678 Org: User:
Start: 04/30/09 End: 09/30/14 Due: 09/30/15

Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors

Phase: N/A Priority: Normal
NCT ID: NCT01929720 Org: User:
Start: 08/31/11 End: 09/30/14 Due: 09/30/15

Daratumumab in Treating Patients With Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02944565 Org: User:
Start: 02/22/17 End: 07/20/17 Due: 07/20/18

Identification of Novel Genetic Factors That Contribute to Risk for Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00276120 Org: User:
Start: 03/31/05 End: 12/31/21 Due: 12/31/22

DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY

Phase: N/A Priority: Normal
NCT ID: NCT06749210 Org: User:
Start: 02/19/25 End: 08/15/25 Due: 08/15/26

Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03654638 Org: User:
Start: 08/15/18 End: 03/09/22 Due: 03/09/23

Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04120454 Org: User:
Start: 06/17/20 End: 12/31/23 Due: 12/31/24

Impact of Dietary Inflammatory Potential on Breast Cancer Risk

Phase: N/A Priority: Normal
NCT ID: NCT05178498 Org: User:
Start: 10/25/23 End: 12/31/35 Due: 12/31/36

Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases

Phase: N/A Priority: Normal
NCT ID: NCT03824327 Org: User:
Start: 02/07/19 End: 12/31/27 Due: 12/31/28

Online Dietary and Resistance Training to Improve Physical Function in Older Cancer Survivors, E-PROOF Trial

Phase: N/A Priority: Normal
NCT ID: NCT06016725 Org: User:
Start: 08/28/23 End: 05/30/25 Due: 05/30/26

Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers

Phase: N/A Priority: Normal
NCT ID: NCT05296005 Org: User:
Start: 12/31/25 End: 12/31/25 Due: 12/31/26

Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen

Phase: N/A Priority: Normal
NCT ID: NCT01682941 Org: User:
Start: 10/31/09 End: 09/07/23 Due: 09/07/24

Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04205071 Org: User:
Start: 11/01/20 End: 12/31/21 Due: 12/31/22

Genetic Counseling Patient Preference Intervention Versus Conventional Genetic Counseling for Women at Elevated Risk for Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05325151 Org: User:
Start: 06/13/22 End: 10/31/25 Due: 10/31/26

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT02760030 Org: User:
Start: 02/16/17 End: 07/31/25 Due: 07/31/26

Educational Intervention - Improving Knowledge and Screening Rates for Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03287453 Org: User:
Start: 04/08/17 End: 09/30/17 Due: 09/30/18

Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00201877 Org: User:
Start: 12/31/04 End: 03/31/12 Due: 03/31/13

Food for Thought - a Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06582615 Org: User:
Start: 10/28/24 End: 12/31/26 Due: 12/31/27

Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00566540 Org: User:
Start: 12/11/07 End: 02/25/10 Due: 02/25/11

Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00143065 Org: User:
Start: 08/31/05 End: 07/31/09 Due: 07/31/10

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Phase: N/A Priority: Normal
NCT ID: NCT04312841 Org: User:
Start: 09/15/20 End: 04/09/24 Due: 04/09/25

Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT05503251 Org: User:
Start: 08/30/22 End: 08/30/25 Due: 08/30/26

Switching to a Vaping Device: Evaluating Risk Reduction Among Quitline Treatment Failures

Phase: N/A Priority: Normal
NCT ID: NCT03502200 Org: User:
Start: 10/15/20 End: 01/31/23 Due: 01/31/24

Perceptions of Vaping Products

Phase: N/A Priority: Normal
NCT ID: NCT06868368 Org: User:
Start: 03/03/25 End: 12/31/26 Due: 12/31/27